Q Therapeutics Board of Directors

Steven J. Borst
President, Chief Executive Officer, and Chairman of the Board of Directors

steve_borst_q-therapeutics.jpg
Mr. Borst serves as President, Chief Executive Officer, and Chairman of Q Therapeutics, Inc. He has led the financial and corporate development activities of the Company since its inception. Mr. Borst has over 30 years of company formation and operating experience in the life sciences sector with a specific focus on biotechnology and medical devices since 2001. He has served in senior executive positions and business development roles including CEO of ACT/PC (NASDAQ:MCK), and VP Business Development of American WholeHealth (NASDAQ:HWAY). Mr. Borst has worked as a venture capital investor, partnering in early-stage equity investments in Cytyc (NASDAQ:HOLX), Sunrise Senior Living (formerly Sunrise Assisted Living – SNRZ), and US Servis (NASDAQ:MCK). He holds a Bachelor of Science (Industrial Engineering and Operations Research) from the University of Michigan and a Master of Management degree from Northwestern University’s J.L. Kellogg Graduate School of Management.  

Deborah Eppstein, Ph.D.
Director

deborah-eppstein-q-therapeutics.jpg

Dr. Eppstein has over 30 years’ experience in the pharmaceutical industry, including 20 years in entrepreneurial roles in biotechnology. She served as President and Chief Executive Officer of Q Therapeutics from 2006 until her retirement in 2015. Dr. Eppstein served as Chief Executive Officer of Altea Therapeutics, Vice President of Corporate Development at TheraTech and Director of Corporate Development and Head of Biochemistry, Virology and Tumor Biology at Syntex (SWX:RO, Roche AG). Dr. Eppstein received a B.A., magna cum laude and Phi Beta Kappa from Grinnell College, a Ph.D. with honors in biochemistry from the University of Arkansas, and conducted research in virology and cell biology as an NIH postdoctoral fellow at the University of California at Santa Barbara.

Peter Grebow, PhD.
Director

peter_grebow-q-therapeutics.jpg
Dr. Grebow has held senior management positions with Cephalon Inc. (now Teva), a biopharmaceutical company, which he joined in January 1991 and served in key positions that included Senior Vice President, Worldwide Business Development; Senior Vice President, Drug Development; Executive Vice President of Technical Operations; and most recently, Executive Vice President of Cephalon Ventures. Prior to joining Cephalon, he served as the Vice President, Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., from 1986 to 1990. Dr. Grebow has also served as a director of Optimer Pharmaceuticals, Inc. since February 2009. He received his undergraduate degree from Cornell University, a Masters of Science in chemistry from Rutgers University, and a Ph.D. in physical biochemistry from the University of California, Santa Barbara.

Peter Barton Hutt, Esq.
Director

peter_barton_hutt_q-therapeutics.jpg
Peter has been a partner of Washington, D.C. based law firm, Covington & Burling, specializing in food and drug law, since 1968, except for the period from 1971 to 1975 when he served as Chief Counsel of the U.S. Food and Drug Administration. Peter received a B.A., magna cum laude, from Yale University; an L.L.B. from Harvard Law School; and an L.L.M. from New York University. He has served on the boards of several publicly traded biotechnology companies and is a member of the Institute of Medicine, National Academy of Sciences. Peter has received numerous honors, including being named by the National Law Journal as one of the 40 best healthcare attorneys in the United States.

Hunter Jackson, Ph.D.
Director

Hunter Jackson, Ph.D.
Dr. Jackson brings to Q Therapeutics more than 30 years' experience in the life science industry. Since April 2014, he has served as Executive Chairman of Navigen Pharmaceuticals, Inc., a company he led as President and Chief Executive Officer from 2006 until his appointment as Executive Chairman. From 1986 through 2006, Dr. Jackson was Chairman and Chief Executive Officer of NPS Pharmaceuticals, Inc., a company he co-founded to pioneer and deliver therapies that transform the lives of patients with rare diseases.
Dr. Jackson currently serves on the boards of Neuroadjuvants, Inc. and Fluorinov, Inc. He earned a Bachelor of Arts degree in American Literature from the University of Illinois, a Ph.D. in Psychobiology from Yale University, and completed postdoctoral work in the Neurosurgery Department at the University of Virginia Medical Center.

Diane Jorkasky, M.D., FACP
Director

dianejorkasky_q-therapeutics.jpg Dr. Jorkasky is a 25-year veteran of the pharmaceutical industry with experience in Phases 1-4 clinical trials, including protocol development, conduct and reporting; site placement strategy; and regulatory interaction. During nine years at Pfizer, Dr. Jorkasky held a number of positions of increasing responsibility advancing to Vice President of Development and Head of Worldwide Clinical Research Operations as well as the leader of the Operational Excellence Board for Development. She was responsible for ensuring that all exploratory development, clinical pharmacology, translational medicine and clinical technology studies were conducted and reported. In this role, she led the execution of over 160 clinical studies per year. At SmithKline Beecham, Dr. Jorkasky served as Vice President and Director of Clinical Pharmacology for North America. Currently, Dr. Jorkasky serves on the Board of Tengion, Inc., a regenerative medicine company focused on the repair and replacement of tissues and organs. She is a member of the Scientific Advisory Board of BioMotive and is the Chief Scientific Officer for Complexa, Inc., a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of inflammatory and metabolic diseases. Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology. She is on the medical school faculties of Yale University, University of Pennsylvania, Uniformed Service of Health Sciences and is a Professor of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. She has published over 100 peer review articles and is a Woodrow Wilson Visiting Fellow.
Dinesh Patel, Ph.D.
Director

dinesh_patel_q-therapeutics.jpg
Q Therapeutics' lead venture investor, Dr. Patel, serves as Chairman of the Company's Board of Directors. Prior to joining in the formation of vSpring Capital in 2002, he served for 14 years as a co-founder, President, Chief Executive Officer and Chairman of TheraTech, Inc., a Salt Lake City drug delivery company that was acquired by Watson Pharmaceuticals. Dr. Patel received his Ph.D. in pharmaceutics from the University of Michigan, an M.S. from Philadelphia College of Pharmacy and Science and a B.S. from Gujarat University, India.
Tom Parks, Ph.D.
Director

Tom Parks
Dr. Parks brings to Q Therapeutics more than 30 years experience in life science research and its translation into therapeutic products. As a faculty member in the Department of Neurobiology & Anatomy at the University of Utah School of Medicine from 1978, he conducted a long-term NIH-funded research program on development of the central auditory nervous system and served as chair of that department from 1992-2007. He was a co-founder of NPS Pharmaceuticals, Inc. and served on its board from 1986-2006. From 2008-2016, Dr. Parks was Vice President for Research and President of the Research Foundation for the University of Utah. He currently serves on the boards of Navigen Pharmaceuticals Inc., SentrX Animal Care Inc., and ConusRx Inc. He is a Fellow of the National Academy of Inventors and a recipient of the Utah Governor's Medal for Science and Technology. Dr. Parks earned a Bachelor of Science degree in Biology from the University of California at Irvine, a Ph.D. in Psychobiology from Yale University, and completed postdoctoral work at the University of Virginia School of Medicine.